Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, posted on X:
“Positive topline results from DESTINY-Breast09!
Trastuzumab deruxtecan (T-DXd) in combination with pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in lPFS compared to taxane, trastuzumab and pertuzumab (THP).”
